Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 6:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 49 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: levomilnacipran Clear all
Completed Phase 4 Interventional Results available

Discontinuation Study of the Durability of Effect of Milnacipran for the Treatment of Fibromyalgia

NCT01014585
View directory record Official record
Conditions
Fibromyalgia
Interventions
Placebo, Milnacipran
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
Not listed
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
58
States / cities
Birmingham, Alabama • Tucson, Arizona • Fresno, California + 51 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2011 · Synced Oct 21, 2026, 6:18 PM EDT
Completed Phase 2 Interventional Results available

A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy

NCT03321526
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
JNJ-42847922, Placebo Matching to JNJ-42847922, Quetiapine XR, Placebo Matching to Quetiapine XR, Selective Serotonin Reuptake Inhibitor (SSRI), Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
50
States / cities
Phoenix, Arizona • Tempe, Arizona • Rogers, Arkansas + 41 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 21, 2026, 6:18 PM EDT
Completed Phase 4 Interventional Results available

Milnacipran for Treatment of Pain in Older Adults With Rheumatoid Arthritis

NCT01225991
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Milnacipran
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
50 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Oct 21, 2026, 6:18 PM EDT
Recruiting Phase 2 Interventional

Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression

NCT06591091
View directory record Official record
Conditions
Depression
Interventions
Clemastine Fumarate, Placebo
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
60 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 21, 2026, 6:18 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Adults With Fatigue Associated With Major Depressive Disorder

NCT01254305
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Levomilnacipran ER, Paroxetine, Sertraline, Citalopram or Fluoxetine., Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
20
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Cerritos, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2014 · Synced Oct 21, 2026, 6:18 PM EDT
Completed Phase 4 Interventional Results available

Milnacipran in the Treatment of Widespread, Non-Joint Pain in Rheumatoid Arthritis

NCT01207453
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Milnacipran, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
24 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 17, 2014 · Synced Oct 21, 2026, 6:18 PM EDT
Completed Phase 3 Interventional Results available

Relapse-Prevention Study With Levomilnacipran ER (F2695 SR) in Patients With Major Depressive Disorder

NCT01085812
View directory record Official record
Conditions
Depression, Major Depressive Disorder
Interventions
Levomilnacipran ER, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
734 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
30
States / cities
Beverly Hills, California • Encino, California • Garden Grove, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 21, 2026, 6:18 PM EDT
Completed Phase 4 Interventional Results available

Effect of Milnacipran on Pain in Fibromyalgia

NCT01288807
View directory record Official record
Conditions
Fibromyalgia
Interventions
Milnacipram
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Oct 21, 2026, 6:18 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of Milnacipran in Pediatric Patients With Primary Fibromyalgia

NCT01328002
View directory record Official record
Conditions
Primary Fibromyalgia
Interventions
Milnacipran, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
13 Years to 17 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
47
States / cities
Birmingham, Alabama • Bullhead City, Arizona • Fresno, California + 38 more
Source: ClinicalTrials.gov public record
Updated May 14, 2019 · Synced Oct 21, 2026, 6:18 PM EDT
Completed Phase 4 Interventional Results available

Study of Milnacipran in Patients With Inadequate Response to Duloxetine for the Treatment of Fibromyalgia

NCT01077375
View directory record Official record
Conditions
Fibromyalgia
Interventions
Placebo, Milnacipran
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 70 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
26
States / cities
Sacramento, California • Cromwell, Connecticut • Danbury, Connecticut + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2012 · Synced Oct 21, 2026, 6:18 PM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Effects of Milnacipran on Pain Processing and Functional MRI in Patients With Fibromyalgia

NCT01173055
View directory record Official record
Conditions
Fibromyalgia
Interventions
milnacipran, Placebo
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Oct 21, 2026, 6:18 PM EDT
Completed Phase 4 Interventional Results available

Drug and Talk Therapy for Fibromyalgia

NCT01038323
View directory record Official record
Conditions
Fibromyalgia
Interventions
CBT and milnacipran, CBT with a placebo, Educational with milnacipran
Other · Behavioral · Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 65 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Oct 21, 2026, 6:18 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder

NCT01034462
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Levomilnacipran ER, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 80 Years
Enrollment
442 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
23
States / cities
Dothan, Alabama • Highlands Ranch, Colorado • Boca Raton, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2013 · Synced Oct 21, 2026, 6:18 PM EDT
Completed Phase 3 Interventional Results available

Study of Milnacipran for the Treatment of Fibromyalgia

NCT00314249
View directory record Official record
Conditions
Fibromyalgia
Interventions
Placebo, Milnacipran 100mg
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,025 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
24
States / cities
Tuscaloosa, Alabama • Fresno, California • Pismo Beach, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2010 · Synced Oct 21, 2026, 6:18 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Savella in Treatment for Provoked Vestibulodynia

NCT01304589
View directory record Official record
Conditions
Vestibulodynia, Vulvodynia
Interventions
Milnacipran
Drug
Lead sponsor
University of Tennessee
Other
Eligibility
18 Years to 54 Years · Female only
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Germantown, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 11, 2018 · Synced Oct 21, 2026, 6:18 PM EDT
Completed Phase 3 Interventional

Study of Milnacipran for the Treatment of Fibromyalgia

NCT00098124
View directory record Official record
Conditions
Fibromyalgia
Interventions
milnacipran hydrochloride
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
80
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 74 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2007 · Synced Oct 21, 2026, 6:18 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Levomilnacipran ER in Adolescent Participants With Major Depressive Disorder

NCT02431806
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Placebo, Levomilnacipran, Fluoxetine
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
12 Years to 17 Years
Enrollment
552 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
48
States / cities
Dothan, Alabama • Tucson, Arizona • Anaheim, California + 40 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2020 · Synced Oct 21, 2026, 6:18 PM EDT
Not listed Phase 4 Interventional

Study to Evaluate the Efficacy of Milnacipran in the Treatment of Pain Due to Osteoarthritis

NCT01329406
View directory record Official record
Conditions
Osteoarthritis
Interventions
Milnacipran, Placebo
Drug
Lead sponsor
Analgesic Solutions
Industry
Eligibility
21 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Natick, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 17, 2011 · Synced Oct 21, 2026, 6:18 PM EDT
Completed Phase 3 Interventional Results available

A Study Of Milnacipran In Patients With Fibromyalgia: Effects On 24 Hour Ambulatory Blood Pressure Monitoring

NCT00618956
View directory record Official record
Conditions
Fibromyalgia
Interventions
Milnacipran hydrochloride, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 70 Years
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
38
States / cities
Birmingham, Alabama • Phoenix, Arizona • Pismo Beach, California + 33 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2009 · Synced Oct 21, 2026, 6:18 PM EDT
Completed Phase 4 Interventional Results available

Trial of Levomilnacipran in Geriatric Depression

NCT02466958
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
levomilnacipran, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
60 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 14, 2019 · Synced Oct 21, 2026, 6:18 PM EDT
Terminated Phase 3 Interventional

Efficacy and Safety of Milnacipran in the Treatment of Fibromyalgia in an Elderly Population

NCT01418651
View directory record Official record
Conditions
Fibromyalgia
Interventions
Savella
Drug
Lead sponsor
Banner Health
Other
Eligibility
65 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Sun City, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 17, 2011 · Synced Oct 21, 2026, 6:18 PM EDT
Completed Phase 4 Interventional Results available

Open-label Milnacipran for Persistent Knee Pain One Year After Total Knee Arthroplasty (TKA)

NCT01780389
View directory record Official record
Conditions
Knee Pain After Total Knee Arthroplasty, Osteoarthritis Pain
Interventions
Open-label flexibly dosed milnacipran
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 6, 2015 · Synced Oct 21, 2026, 6:18 PM EDT
Completed Phase 4 Interventional Results available

The Effects of Milnacipran on Sleep Disturbance in Fibromyalgia

NCT01234675
View directory record Official record
Conditions
Sleep Disorders, Fibromyalgia, Sleep
Interventions
Milnacipran, Placebo
Drug
Lead sponsor
Mansoor Ahmed M.D.
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Middleburg Heights, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Oct 21, 2026, 6:18 PM EDT
Completed Not applicable Interventional Results available

Study Evaluated the Effectiveness of Milnacipran to Reduce Pain Levels in Individuals With Chronic Migraine

NCT01393522
View directory record Official record
Conditions
Chronic Migraine
Interventions
Milnacipran, Placebo
Drug
Lead sponsor
Timothy Smith
Other
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
St Louis, Missouri • Greensboro, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 12, 2022 · Synced Oct 21, 2026, 6:18 PM EDT